Immunotherapy in renal cancer: present in the context of the past


Doc. MUDr. Jan Novotný, Ph.D.

Onkologi, Sunderby Sjukhus, Luieá, Švédsko



Metastatic renal carcinoma belongs to the class of malignancies in which an immunologic response is described, observed and used as a treatment strategy. In 2019, four randomized controlled trials studying four novel immunotherapy-based regimens have been published (nivolumab with ipilimumab, atezolizumab plus bevacizumab, avelumab plus axitinib and pembrolizumab with axitinib). Some of these regimens exert a survival advantage to the appropriately selected patients. All aspects of these studies are discussed in presented paper.


Key words

renal cancer, immunotherapy, PD-1 inhibitor, PD-L1 inhibitor, targeted therapy



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...